Dr Matteo Lambertini speaks with ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the conference highlights in breast cancer research.
He first discusses results from two studies in the metastatic HER2-positive setting, the SOPHIA trial and the NALA trial, before going on to discuss two studies in hormone receptor positive metastatic breast cancer, the MONALEESA-7 trial and a Korean trial investigating whether it's better to start with chemotherapy or endocrine therapy.
Dr Lambertini then reports findings from an international, retrospective study that he presented on the safety of pregnancy following breast cancer in patients with a BRCA mutation.
He concludes by discussing the GeparOLA and the GIM4 trials.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.